RAS mutations and oncogenesis: Not all RAS mutations are created equally

Frontiers in Genetics

Volumn 2, Issue JAN, 2012, Pages

  Miller, Mark Steven ^a   Miller, Lance D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Mutation; Ras; Tumorigenesis

Indexed keywords

RODENTIA;

EID: 84863640576     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2011.00100     Document Type: Review

References (104)

1. Agbunag, C., and Bar-Sagi, D. (2004). Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res. 64, 5659-5663.
2. Barbacid, M. (1987). Ras genes. Annu. Rev. Biochem. 56, 779-827.
3. Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. R., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., Frohling, S., Chan, E. M., Sos, M. L., Michel, K., Mermel, C., Silver, S. J., Weir, B. A., Reiling, J. H., Sheng, Q., Gupta, P. B., Wadlow, R. C., Le, H., Hoersch, S., Wittner, B. S., Ramaswamy, S., Livingston, D. M., Sabatini, D. M., Meyerson, M., Thomas, R. K., Lander, E. S., Mesirov, J. P., Root, D. E., Gilliland, D. G., Jacks, T., and Hahn, W. C. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462,108-112.
4. Beer, D. G., Kardia, S. L., Huang, C. C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., Lizyness, M. L., Kuick, R., Hayasaka, S., Taylor, J. M., Iannettoni, M. D., Orringer, M. B., and Hanash, S. (2002) Gene-expression profiles predict survival of patients with lung adenocarci-noma. Nat. Med. 8, 816-824.
5. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., Loda, M., Weber, G., Mark, E. J., Lander, E. S., Wong, W., Johnson, B. E., Golub, T. R., Sug-arbaker, D. J., and Meyerson, M. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocar-cinoma subclasses. Proc. Natl. Acad. Sci. U.S.A. 98, 13790-13795.
6. Bonner, A. E., Lemon, W. J., Dev-ereux, T. R., Lubet, R. A., and You, M. (2004). Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarci-nomas. Oncogene 23,1166-1176.
7. Bos, J. L. (1989). Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689.
8. Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., van Boom, J. H., van der Eb, A. J., and Vogel-stein, B. (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-297.
9. Bounacer, A., McGregor, A., Skinner, J., Bond, J., Poghosyan, Z., and Wynford-Thomas, D. (2004). Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways. Oncogene 23, 7839-7845.
10. Campbell, S. L., Khosravi-Far, R., Ross-man, K. L., Clark, G. J., and Der, C. J. (1998). Increasing complexity of Ras signaling. Oncogene 17,1395-1413.
11. Cerny, W L., Mangold, K. A., and Scarpelli, D. G. (1992). K-rasmutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res. 52, 4507-4513.
12. Cespedes, M. V., Sancho, F. J., Guerrero, S., Parreno, M., Casanova, I., Pavon, M. A., Marcuello, E., Trias, M., Cas-cante, M., Capella, G., and Mangues, R. (2006). K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis 27, 2190-2200.
13. Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., and Philips, M. R. (2002). Ras signalling on the endo-plasmic reticulum and the Golgi. Nat. Cell Biol. 4, 343-350.
14. Colby, W W, Hayflick, J. S., Clark, S. G., and Levinson, A. D. (1986). Biochemical characterization of polypeptides encoded by mutated human Ha-ras1 genes. Mol Cell. Biol. 6, 730-734.
15. Conti, C. J. (1992). "Mutations of genes of the ras family in human and experimental tumors," in Comparative Molecular Carcinogenesis, eds A. J. P. Klein-Szanto, M. W. Anderson, J. C. Barrett, and T. J. Slaga (New York: Wiley-Liss, Inc.), 357-378.
16. Creighton, C. J., Bromberg-White, J. L., Misek, D. E., Monsma, D. J., Bri-chory, F., Kuick, R., Giordano, T. J., Gao, W., Omenn, G. S., Webb, C. P., and Hanash, S. M. (2005). Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol. Cancer Res. 3, 119-129.
17. Dance-Barnes, S. T., Kock, N. D., Floyd, H. S., Moore, J. E., Mosley, L. J., D'Agostino, R. B. Jr., Pettenati, M. J., and Miller, M. S. (2008). Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors. Toxicol. Appl. Pharmacol. 231,77-84.
18. Davis, M. F., Vigil, D., and Campbell, S. L. (2011) Regulation of Ras proteins by reactive nitrogen species. Free Radic. Biol. Med. 51, 565-575.
19. De, R. W., Jonker, D. J., Di, N. F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piesse-vaux, H., Van, C. E., O'Callaghan, C. J., Khambata-Ford, S., Zalcberg, J. R., Simes, J., Karapetis, C. S., Bardelli, A., and Tejpar, S. (2010). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820.
20. Del Villar, K., Dorin, D., Sattler, I., Urano, J., Poullet, P., Robinson, N., Mitsuzawa, H., and Tamanoi, F. (1996). C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Biochem. Soc. Trans. 24, 709-713.
21. Der, C. J., Finkel, T., and Cooper, G. M. (1986). Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 44, 167-176.
22. Ehrhardt, A., David, M. D., Ehrhardt, G. R., and Schrader, J. W. (2004). Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen. Mol. Cell. Biol. 24, 6311-6323.
23. K-ras modulates the cell cycle viaboth positive and negative regulatory pathways
24. Fasano, O., Aldrich, T., Tamanoi, F., Taparowsky, E., Furth, M., and Wigler, M. (1984). Analysis of the transforming potential of the human H-ras gene by random muta-genesis. Proc. Natl. Acad. Sci. U.S.A. 81,4008-4012.
25. Filchtinski, D., Sharabi, O., Ruppel, A., Vetter, I. R., Herrmann, C., and Shif-man, J. M. (2010). What makes Ras an efficient molecular switch: a computational, biophysical, and structural study of Ras-GDP interactions withmutants of Raf.J. Mol. Biol. 399, 422-435.
26. Finkelstein, S. D., Sayegh, R., Bakker, A., and Swalsky, P. (1993a). Determination of tumor aggressiveness in col-orectal cancer by K- ras-2 analysis. Arch. Surg. 128, 526-531; discussion 531-532.
27. Finkelstein, S. D., Sayegh, R., Chris-tensen,S., and Swalsky, P. A. (1993b). Genotypic classification of colorec-tal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 71, 3827-3838.
28. Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., and Varmus, H. E. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15,3249-3262.
29. Fleming, J. B., Shen, G. L., Holloway, S. E., Davis, M., and Brekken, R. A. (2005). Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol. Cancer Res. 3, 413-423.
30. Floyd, H. S., Farnsworth, C. L., Kock, N. D., Mizesko, M. C., Little, J. L., Dance, S. T., Everitt, J., Tichelaar, J. W., Whitsett, J. A., and Miller, M. S. (2005). Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. Carcinogenesis 26,2196-2206.
31. Floyd, H. S., Jennings-Gee, J. E., Kock, N. D., and Miller, M. S. (2006). Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-ras(G12C) expressing mice. Mol. Carcinog. 45,506-517.
32. Ford, E., Hughes, M. N., and Wardman, P. (2002). Kinetics of the reactions of nitrogen dioxide with glutathione, cysteine, and uric acid at physiological pH. Free Radic. Biol. Med. 32, 1314-1323.
33. Garassino, M. C., Marabese, M., Rus-coni, P., Rulli, E., Martelli, O., Farina, G., Scanni, A., and Broggini, M. (2011). Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann. Oncol. 22,235-237.
34. Gibbs, J. B., Sigal, I. S., Poe, M., and Scolnick, E. M. (1984a). Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc. Natl. Acad. Sci. U.S.A. 81, 5704-5708.
35. Gibbs, J. B., Ellis, R. W., and Scolnick, E.M. (1984b). Autophosphorylation of v-Ha-ras p21 is modulated by amino acid residue 12. Proc. Natl. Acad. Sci. U.S.A. 81,2674-2678.
36. Gille, H., and Downward, J. (1999). Multiple ras effector pathways contribute to G(1) cell cycle progression. J. Biol. Chem. 274, 22033-22040.
37. Grady, W. M., and Markowitz, S. D. (2002). Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 3, 101-128.
38. Gressani, K. M., Leone-Kabler, S. L., O'Sullivan, M. G., Case, L. D., Malkinson, A. M., and Miller, M. S. (1999). Strain-specific lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to buty-lated hydroxytoluene. Carcinogenesis 20,2159-2165.
39. Gryfe, R., Swallow, C., Bapat, B., Red-ston, M., Gallinger, S., and Couture, J. (1997). Molecular biology of col-orectal cancer. Curr. Probl. Cancer 21,233-300.
40. Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., and Bar-bacid, M. (2003). Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120.
41. Guerrero, S., Casanova, I., Farre, L., Mazo, A., Capella, G., and Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 60, 6750-6756.
42. Hancock, J. F. (2003). Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4, 373-384.
43. Heo, J., and Campbell, S. L. (2006). Ras regulation by reactive oxygen and nitrogen species. Biochemistry 45,2200-2210.
44. Heo, J., Prutzman, K. C., Mocanu, V., and Campbell, S. L. (2005). Mechanism of free radical nitric oxide-mediated Ras guanine nucleotide dissociation. J. Mol. Biol. 346, 1423-1440.
45. Heo, J., Raines, K. W., Mocanu, V., and Campbell, S. L. (2006). Redox regulation of RhoA. Biochemistry 45, 14481-14489.
46. Hruban, R. H., van Mansfeld, A. D., Offerhaus, G. J., van Weering, D. H., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose, K. K., Cameron, J. L., and Bos, J. L. (1993). K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol. 143, 545-554.
47. Huncharek, M., Muscat, J., and Geschwind, J. F. (1999). K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20,1507-1510.
48. Hwang, D. Y., and Cohen, J. B. (1997). A splicing enhancer in the 3;-terminal c-H-ras exon influences mRNA abundance and transforming activity.J. Virol. 71, 6416-6426.
49. Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., and Tuve-son, D. A. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248.
50. Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huber-man, K., Ricarte Filho, J. C., Persaud, Y., Levine, D. A., Fagin, J. A., Jhan-war, S. C., Mariadason, J. M., Lash, A., Ladanyi, M., Saltz, L. B., Heguy, A., Paty, P. B., and Solit, D. B. (2010). Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 70, 5901-5911.
51. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA CancerJ. Clin. 60,277-300.
52. Jennings-Gee, J. E., Moore, J. E., Xu, M., Dance, S. T., Kock, N. D., McCoy, T. P., Carr, J. J., and Miller, M. S. (2006). Strain-specific induction of murine lung tumors following in utero exposure to 3-methylcholanthrene. Mol. Carcinog. 45, 676-684.
53. Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., and Jacks, T. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116.
54. Jourd'heuil, D., Jourd'heuil, F. L., and Feelisch, M. (2003). Oxidation and nitrosation of thiols at low micro-molar exposure to nitric oxide. Evidence for a free radical mechanism. J. Biol. Chem. 278, 15720-15726.
55. Kassie, F., Anderson, L. B., Higgins, L., Pan, Y., Matise, I., Negia, M., Upad-hyaya, P., Wang, M., and Hecht, S. S. (2008). Chemopreventive agents modulate the protein expression profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumors in A/J mice. Carcinogenesis 29,610-619.
56. Keohavong, P., DeMichele, M. A., Melacrinos, A. C., Landreneau, R. J., Weyant, R. J., and Siegfried, J. M. (1996). Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin. Cancer Res. 2,411-418.
57. Kerkhoff, E., Fedorov, L. M., Siefken, R., Walter, A. O., Papadopoulos, T., and Rapp, U. R. (2000). Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ. 11, 185-190.
58. Kjeldgaard, M., Nyborg, J., and Clark, B. F. (1996). The GTP binding motif: variations on a theme. FASEB J. 10, 1347-1368.
59. Leone-Kabler, S. L., Wessner, L. L., McEntee, M. F., D'Agostino, R. B., and Miller, M. S. (1997). Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors. Carcinogenesis 18, 1163-1168.
60. Li, Z. H., Zheng, J., Weiss, L. M., and Shibata, D. (1994a). c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am. J. Pathol. 144, 303-309.
61. Li, E. E., Heflich, R. H., Bucci, T. J., Man-janatha, M. G., Blaydes, B. S., and Delclos,K.B. (1994b). Relationships of DNA adduct formation, K-ras activating mutations and tumori-genic activities of 6-nitrochrysene and its metabolites in the lungs of CD-1 mice. Carcinogenesis 15, 1377-1385.
62. Lukman, S., Grant, B. J., Gorfe, A. A., Grant, G. H., and McCammon, J. A. (2010). The distinct conformational dynamics of K-RasandH-RasA59G. PLoS Comput Biol. 6. e1000922. doi:10.1371/journal.pcbi.1000922
63. Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K. K., and Elledge, S. J. (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848.
64. Malumbres, M., and Barbacid, M. (2003). RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459-465.
65. Manne, V., Bekesi, E., and Kung, H. E (1985). Ha-ras proteins exhibit GTPase activity: point mutations that activate Ha-ras gene products result in decreased GTPase activity. Proc. Natl. Acad. Sci. U.S.A. 82, 376-380.
66. McGrath, J. P., Capon, D. J., Goeddel, D. V., and Levinson, A. D. (1984). Comparative biochemical properties of normal and activated human ras p21 protein. Nature 310, 644-649.
67. Meuwissen, R., Linn, S. C., van, d. V., Mooi, W. J., and Berns, A. (2001). Mouse model for lung tumorigene-sis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20, 6551-6558.
68. Miller, M. S. (1994). Transplacental lung carcinogenesis: a pharmacogenetic mouse model for the modulatory role of cytochrome P450 1A1 on lung cancer initiation. Chem. Res. Toxicol. 7,471-481.
69. Mitsudomi, T., Steinberg, S. M., Oie, H. K., Mulshine, J. L., Phelps, R., Viallet, J., Pass, H., Minna, J. D., and Gazdar, A. F. (1991). ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 51,4999-5002.
70. Miura, K., Bowman, E. D., Simon, R., Peng, A. C., Robles, A. I., Jones, R. T., Katagiri, T., He, P., Mizukami, H., Charboneau, L., Kikuchi, T., Liotta, L. A., Nakamura, Y., and Harris, C. C. (2002). Laser capture microdis-section and microarray expression analysis of lung adenocarci-noma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res. 62, 3244-3250.
71. Mizesko, M. C., Grewe, C., Grabner, A., and Miller, M. S. (2001). Alterations at the Ink4a locus in transplacen-tally induced murine lung tumors. Cancer Lett. 172,59-66.
72. Moon, A. (2006). Differential functions of Ras for malignant phenotypic conversion. Arch. Pharm. Res. 29, 113-122.
73. Nielsen, K. H., Gredsted, L., Broach, J. R., and Willumsen, B. M. (2001). Sensitivity of wild type and mutant ras alleles to Ras specific exchange factors: identification of factor specific requirements. Oncogene 20, 2091-2100.
74. Nuzum, E. O., Malkinson, A. M., and Beer, D. G. (1990). Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. Mol. Carcinog. 3, 287-295.
75. Ogino, S., Meyerhardt, J. A., Irahara, N., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Schaefer, P., Whit-tom, R., Hantel, A., Benson, A. B., III, Goldberg, R. M., Bertagnolli, M. M., and Fuchs, C. S. (2009). KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res. 15,7322-7329.
76. Omerovic, J., Hammond, D. E., Clague, M. J., and Prior, I. A. (2008). Ras isoform abundance and signalling in human cancer cell lines. Oncogene 27, 2754-2762.
77. Raines, K. W., Bonini, M. G., and Campbell, S. L. (2007). Nitric oxide cell signaling: S-nitrosation of Ras super-family GTPases. Cardiovasc. Res. 75, 229-239.
78. Ratner, E., Lu, L., Boeke, M., Barnett, R., Nallur, S., Chin, L. J., Pelletier, C., Blitzblau, R., Tassi, R., Paran-jape, T., Hui, P., Godwin, A. K., Yu, H., Risch, H., Rutherford, T., Schwartz, P., Santin, A., Matloff, E., Zelterman, D., Slack, F. J., and Wei-dhaas, J. B. (2010). A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 70, 6509-6515.
79. Recktenwald, C. V., Kellner, R., Lichten-fels, R., and Seliger, B. (2008). Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Cancer Res. 68, 10086-10093.
80. Reuther, G. W., and Der, C. J. (2000). The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell Biol. 12, 157-165.
81. Reynolds, S. H., Wiest, J. S., Devereux, T. R., Anderson, M. W., and You, M. (1992). "Protooncogene activation in spontaneously occurring and chemically induced rodent and human lung tumors," in Comparative Molecular Carcinogenesis, eds A. J. P. Klein-Szanto, M. W. Anderson, J. C. Barrett, and T. J. Slaga (NewYork: Wiley-Liss, Inc.), 303-320.
82. Rodenhuis, S., and Slebos, R. J. (1992). Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 52, 2665s-2669s.
83. Rosell, R., Li, S., Skacel, Z., Mate, J. L., Maestre, J., Canela, M., Tolosa, E., Armengol, P., Barnadas, A., and Ariza, A. (1993). Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8, 2407-2412.
84. Rosell, R., Monzo, M., Pifarre, A., Ariza, A., Sanchez, J. J., Moreno, I., Manuel, J., Lopez, M. P., Abad, A., and Maria de Anta, J. (1996). Molecular staging of non-small cell lung cancer according to K- ras genotypes. Clin. Cancer Res. 2, 1083-1086.
85. Scholl, C., Frohling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., Dohner, K., Bullinger, L., Sandy, P., Boehm, J. S., Root, D. E., Jacks, T., Hahn, W. C., and Gilliland, D. G. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834.
86. Schrammel, A., Gorren, A. C., Schmidt, K., Pfeiffer, S., and Mayer, B. (2003) S-nitrosation of glutathione by nitric oxide, peroxynitrite, and (*)NO/O(2)(*-). Free Radic. Biol. Med. 34, 1078-1088.
87. Seeburg, P. H., Colby, W. W., Capon, D. J., Goeddel, D. V., and Levinson, A. D. (1984). Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312, 71-75.
88. Siegfried, J. M., Gillespie, A. T., Mera, R., Casey, T. J., Keohavong, P., Testa, J. R., and Hunt, J. D. (1997). Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol. Biomarkers Prev. 6, 841-847.
89. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., and Settleman, J. (2009). A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15,489-500.
90. Smith, G., Bounds, R., Wolf, H., Steele, R. J., Carey, F. A., and Wolf, C. R. (2010). Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours -implications for personalised cancer medicine. Br. J. Cancer 102, 693-703.
91. Sweet, R. W., Yokoyama, S., Kamata, T., Feramisco, J. R., Rosenberg, M., and Gross, M. (1984). The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311, 273-275.
92. Sweet-Cordero, A., Mukherjee, S., Sub-ramanian, A., You, H., Roix, J. J., Ladd-Acosta, C., Mesirov, J., Golub, T. R., and Jacks, T. (2005). An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37, 48-55.
93. To, M. D., Wong, C. E., Karnezis, A. N., Del, R. R., Di, L. R., and Balmain, A. (2008). Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat. Genet. 40,1240-1244.
94. Vicent, S., Chen, R., Sayles, L. C., Lin, C., Walker, R. G., Gillespie, A. K., Subramanian, A., Hinkle, G., Yang, X., Saif, S., Root, D. E., Huff, V., Hahn, W. C., and Sweet-Cordero, E. A. (2010). Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J. Clin. Invest. 120, 3940-3952.
95. Virtanen, C., Ishikawa, Y., Honjoh, D., Kimura, M., Shimane, M., Miyoshi, T., Nomura, H., and Jones, M. H. (2002). Integrated classification of lung tumors and cell lines by expression profiling. Proc. Natl. Acad. Sci. U.S.A. 99, 12357-12362.
96. Vizan, P., Boros, L. G., Figueras, A., Capella, G., Mangues, R., Bassil-ian, S., Lim, S., Lee, W. N., and Cascante, M. (2005). K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice fibroblasts. Cancer Res. 65,5512-5515.
97. Westra,W.H.,Baas,I.O.,Hruban,R.H., Askin, F. B., Wilson, K., Offerhaus, G. J., and Slebos, R. J. (1996). K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 56, 2224-2228.
98. Westra, W. H., Slebos, R. J., Offerhaus, G. J., Goodman, S. N., Evers, S. G., Kensler, T. W., Askin, F. B., Rodenhuis, S., and Hruban, R. H. (1993). K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adeno-carcinoma of the lung. Cancer 72, 432-438.
99. Wikman, H., Kettunen, E., Seppa-nen, J. K., Karjalainen, A., Holl-men, J., Anttila, S., and Knuutila, S. (2002). Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21, 5804-5813.
100. Williams, J. G., Pappu, K., and Campbell, S. L. (2003). Structural and biochemical studies of p21Ras S-nitrosylation and nitric oxide-mediated guanine nucleotide exchange. Proc. Natl. Acad. Sci. U.S.A. 100,6376-6381.
101. Yao, R., Wang, Y., Lubet, R. A., and You, M. (2002). Differentially expressed genes associated with mouse lung tumor progression. Oncogene 21, 5814-5821.
102. Young, A., Lyons, J., Miller, A. L., Phan, V. T., Alarcon, I. R., and McCormick, E (2009). Ras signaling and therapies. Adv. Cancer Res. 102, 1-17.
103. Zhang, B., Zhang, Y., Shacter, E., and Zheng, Y (2005). Mechanism of the guanine nucleotide exchange reaction of Ras GTPase - evidence for a GTP/GDP displacement model. Biochemistry 44,2566-2576.
104. Zuber, J., Tchernitsa, O. I., Hinz-mann, B., Schmitz, A. C., Grips, M., Hellriegel, M., Sers, C., Rosen-thal, A., and Schafer, R. (2000). A genome-wide survey of RAS transformation targets. Nat. Genet. 24, 144-152.